Bone marrow microRNA-34a is a good indicator for response to treatment in acute myeloid leukemia
Oncology Research · 2024 · 32 (3) · 577-584
DOI: 10.32604/or.2023.043026 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Research, 2024. Verfasst von Mona S Abdellateif und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Biology, Medical Biochemistry and Molecular Biology, National Cancer Institute, Cairo University, Cairo, 11976, Egypt. Hauptthemen laut MEDLINE: MicroRNAs, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background: microRNA-34a (miR-34a) had been reported to have a diagnostic role in acute myeloid leukemia (AML). However, its value in the bone marrow (BM) of AML patients, in addition to its role in response to therapy is still unclear. The current study was designed to assess the diagnostic, prognostic, and predictive significance of miR-34a in the BM of AML patients. Methods: The miR-34a was assessed in BM aspirate of 82 AML patients in relation to 12 normal control subjects using qRT-PCR. The data were assessed for correlation with the relevant clinical criteria, response to therapy, disease-free survival (DFS), and overall survival (OS) rates. Results: miR-34a was significantly downregulated in AML patients [0.005 (3.3 × 10-6-1.32)], compared to the control subjects [0.108 (3.2 × 10-4-1.64), p = 0.021]. The median relative quantification (RQ) of miR-34a was 0.106 (range; 0-32.12). The specificity, sensitivity, and area under the curve (AUC) for the diagnosis of AML were (58.3%, 69.5%, 0.707, respectively, p = 0.021). patients with upregulated miR-34a showed decreased platelets count
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cancer Biology, Medical Biochemistry and Molecular Biology, National Cancer Institute, Cairo University, Cairo, 11976, Egypt.
- Department of Clinical Pathology, National Cancer Institute, Cairo University, Cairo, 11976, Egypt.
Zitieren
APA
Abdellateif, M. S., Hassan, N. M., Kamel, M. M., & El-Meligui, Y. M. (2024). Bone marrow microRNA-34a is a good indicator for response to treatment in acute myeloid leukemia. Oncology Research, 32(3), 577-584. https://doi.org/10.32604/or.2023.043026
Vancouver
Abdellateif MS, Hassan NM, Kamel MM, El-Meligui YM. Bone marrow microRNA-34a is a good indicator for response to treatment in acute myeloid leukemia. Oncology Research. 2024;32(3):577-584. doi:10.32604/or.2023.043026
BibTeX
@article{Abdellateif2024,
author = {Abdellateif, Mona S and Hassan, Naglaa M and Kamel, Mahmoud M and El-Meligui, Yomna M},
title = {Bone marrow microRNA-34a is a good indicator for response to treatment in acute myeloid leukemia},
journal = {Oncology Research},
year = {2024},
volume = {32},
number = {3},
pages = {577--584},
doi = {10.32604/or.2023.043026}
}
EUVIMED